Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Functional Usability and Feasibility Testing of the Profound Matrix™ System

NCT06192550 · View on ClinicalTrials.gov ↗

Study Summary

This is a non-randomized, multi-center, open-label clinical trial evaluating the efficacy and clinical feasibility of the Profound Matrix device for electrocoagulation and for treatment of wrinkles and acne scars. Subjects will receive up to three (3) treatments with the Matrix Pro applicator or up to five (5) treatments with the Sublime and/or Sublative Radiofrequency (RF) applicators.

Interventions

  • DEVICE Profound Matrix™ System

Study Locations (5)

New York

  • NY Derm — New York
  • OptiSkin — New York

Massachusetts

  • Candela Institue for Excellence — Marlborough

North Carolina

  • Laser & Vein Specialists of the Carolinas — Charlotte

Other

  • Syneron Medical — Yokneam Illit

Trial Details

FieldValue
Enrollment Target 193 participants
Start Date 2020-10-28
Est. Completion 2023-12-29
Phase NA

Sponsor

Candela Corporation

6 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06192550

The ClinicalTrials.gov registry entry for NCT06192550 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 193 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Candela Corporation, which has 6 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Wrinkle appearing as the primary indexed condition, and to 1 intervention — of which Profound Matrix™ System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06192550 reports 5 study locations spanning 4 distinct geographic areas — top geographies include New York, Massachusetts, North Carolina. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06192550 about?

NCT06192550 is a clinical study titled "Functional Usability and Feasibility Testing of the Profound Matrix™ System". This is a non-randomized, multi-center, open-label clinical trial evaluating the efficacy and clinical feasibility of the Profound Matrix device for electrocoagulation and for treatment of wrinkles and acne scars. Subjects will receive up to three (3) treatments with the Matrix Pro applicator or up ...

What is the current status of trial NCT06192550?

This trial is currently completed. It is a NA study. The enrollment target is 193 participants. The study started on 2020-10-28. Estimated completion is 2023-12-29.

What conditions does trial NCT06192550 study?

This clinical trial studies the following conditions: Wrinkle, Acne Scars - Mixed Atrophic and Hypertrophic. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06192550?

The interventions under investigation include: Profound Matrix™ System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06192550?

This trial is sponsored by Candela Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06192550 being conducted?

This trial has 5 study locations across Massachusetts, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial